Vaccine with Virus-Like Nanoparticles Effective Treatment for RSV, Study Finds

August 5, 2015

(Nanotechnology Now) – A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University. The findings, published on July 14 in the International Journal of Nanomedicine, suggest this vaccine induces long-term protection against RSV and could serve as a novel treatment option for this disease. There is currently no licensed RSV vaccine.